#863: Elad Gil, Consigliere to Empire Builders — How to Spot Billion-Dollar Companies Before Everyone Else, The Misty AI Frontier, How Coke Beat Pepsi, When Consensus Pays, and Much More

Elad Gil ( @eladgil ) is CEO of Gil & Co, a multi-stage investment firm, holding company, and operating company working on the world’s most advanced technologies. Elad is a serial entrepreneur, operating executive, and investor or advisor to private companies, including AirBnB, Anduril, Coinbase, Figma, Instacart, OpenAI, SpaceX, and Stripe. He was previously VP of Corporate Strategy at Twitter and started mobile at Google. He was the founder and CEO of Mixerlabs and Color. Elad is the author of the bestseller High Growth Handbook: Scaling Startups from 10 to 10,000 People . This episode is brought to you by: Matic the intelligent robot vacuum and mop that navigates obstacles and needs no babysitting: MaticRobots.com/Tim AG1 all-in-one nutritional supplement: DrinkAG1.com/Tim Eight Sleep Pod Cover 5 sleeping solution for dynamic cooling and heating: EightSleep.com/Tim Helix Sleep premium mattresses: HelixSleep.com/Tim Timestamps [00:00:00] Start. [00:02:21] What’s the “AI personal IPO” that just quietly happened across Silicon Valley? [00:05:28] Tens to hundreds of millions per researcher: What top AI pay packages actually look like. [00:06:44] The compute ceiling: Why Korean memory fabs are the unlikely bottleneck throttling every AI lab on earth. [00:11:11] From zero to $30B run rate: The fastest revenue ramps in the history of capitalism. [00:17:24] The dot-com survival rate was one in 100. Buckle up, AI founders. [00:20:35] Your value-maximizing window: Why the next 12–18 months may be as good as it gets. [00:21:32] Durable advantage — and why the AI market is an oligopoly (for now). [00:24:12] Exit options for AI founders: labs, hyperscalers, vertical players, and the underrated merger of equals. [00:28:11] Math, biology, and intuitive leaps: Elad’s pre-investing background. [00:29:42] Elad’s revisionist genesis story. [00:30:50] Go where the cluster is: 91% of global AI private market cap lives in a 10×10 mile square. [00:33:20] The accidental investor: Patrick Collison walks, Airbnb intros, and deals that just happened. [00:34:37] Want money? Ask for advice. Want advice? Ask for money. [00:35:00] The High Growth Handbook : Tactical guide, not bedtime reading. [00:35:41] Market first, team second — with a Perplexity-and-Anduril asterisk. [00:37:43] Smoke in the distance: AlexNet and the transformative GPT-3 moment. [00:45:15] AI cold-reading: Feeding photos to the model and getting eerily accurate personality reads. [00:48:56] Has Elad ever done a retrospective on his own investing? [00:52:13] Power laws are terrifying: 10 companies, 80% of returns, two decades. [00:55:53] Avoiding science projects, and how SPACs accidentally saved hard tech investing. [00:59:20] The one-belief framework: Coinbase = crypto index. Stripe = e-commerce index. That’s the whole memo. [01:00:54] Due diligence theater vs. the one question that actually matters. [01:02:13] The four-year vest is a relic: How venture capital ate growth investing. [01:07:16] Boards as in-laws: You can’t fire them, so choose wisely. [01:09:47] “Valuation is temporary. Control is forever.” — Naval Ravikant, as quoted by Elad, as relayed to you. [01:11:30] How great companies actually grew: toolbars, name-targeted ads, and billions in distribution spend. [01:15:36] Selling software vs. selling labor hours: The real shift generative AI made. [01:18:40] Spotting a great market: regulatory shifts, technology shifts, and Hashi getting bought by IBM. [01:21:28] Fake TAM, real TAM, and the Coke CEO who realized he wasn’t in the soda business. [01:22:47] Right now, consensus is just correct. Save the contrarianism for later. [01:25:15] Market entry vs. market disruption: SpaceX launched rockets, then disrupted the internet. [01:26:16] How Elad learns: X, papers, 20-minute calls with the right people — and four AI models running in parallel. [01:27:15] Deep dive: ADHD, autism, and why diagnostic rates soared without more people actually having it. [01:33:40] Longevity for rea